Literature DB >> 30617445

Clinical features, radiological profiles, and surgical outcomes of primary intracranial solitary plasmacytomas: a report of 17 cases and a pooled analysis of individual patient data.

Xiu-Jian Ma1, Da Li1, Liang Wang1, Shu-Yu Hao1, Li-Wei Zhang1, Jun-Ting Zhang1, Zhen Wu2.   

Abstract

PURPOSE: We aim to delineate the clinical characteristics of patients with primary intracranial solitary plasmacytoma (PISPC) and prognostic factors for their outcomes.
METHODS: This study retrospectively reviewed 17 patients with PISPC from our center and an additional 70 cases of PISPC published previously to analyze outcome predictors.
RESULTS: The entire cohort included 38 (43.7%) males and 49 (56.3%) females with a mean age of 54 years. Skull base tumors were found in 49 (56.3%) patients. Gross total resection (GTR) was achieved in 31 (35.6%) patients. Postoperative adjuvant treatments, including radiotherapy (RT) alone, chemotherapy (CMT) alone, and RT + CMT were administered in 49 (56.3%) patients, 3 (3.5%) patients, and 16 (18.4%) patients, respectively. After a median follow-up of 24 (mean 42.4) months, the 5-year disease progression-free survival (PFS), recurrence-free survival (RFS), multiple myeloma (MM)-free survival (MMFS), and overall survival (OS) were 52.9%, 76.2%, 69.6%, and 76.1%, respectively. Multivariate analysis unveiled that a skull base tumor location (HR 2.395, p = 0.040) and no RT (HR 3.115, p = 0.004) were negative prognostic factors for PFS, no RT (HR 10.526, p = 0.003) for RFS, each 1-year increase in age (HR 1.039, p = 0.049) for MMFS, and increasing age (HR 1.052, p = 0.043) and CMT (HR 6.022, p = 0.005) were risk factors for OS. However, GTR did not benefit the aforementioned outcomes.
CONCLUSION: For patients with presumed PISPC, a biopsy followed by RT is recommended for skull base PISPC. However, the role of CMT is still not clear. Our findings need to be verified in a larger prospective cohort in the future. Systematic review registration number CRD42018098782.

Entities:  

Keywords:  Chemotherapy; Multiple myeloma development; Primary intracranial solitary plasmacytoma; Radiotherapy

Mesh:

Year:  2019        PMID: 30617445     DOI: 10.1007/s11060-019-03089-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  4 in total

1.  Anterior petrosal approach for petroclival solitary plasmacytoma.

Authors:  José Orlando de Melo Junior; Luiz Antônio da Silva Lavradas Junior; José Alberto Landeiro
Journal:  Surg Neurol Int       Date:  2022-05-13

2.  Novel case of primary intracranial solitary plasmacytoma presenting with significant intratumoral hemorrhage.

Authors:  Daisuke Sato; Shunsaku Takayanagi; Hirokazu Takami; Tetsuaki Iwamoto; Masashi Nomura; Shohei Nambu; Masako Ikemura; Shota Tanaka; Nobuhito Saito
Journal:  Surg Neurol Int       Date:  2022-04-22

3.  Intracranial plasmacytoma arising from dura mater secondary to multiple myeloma and presenting with sudden lethal intracerebral hemorrhage: A case report and literature review.

Authors:  Koki Onodera; Kota Kurisu; Seiji Takebayashi; Juro Sakurai; Tohru Kobayashi; Rina Kobayashi; Shuho Goto; Katsumi Takizawa
Journal:  Surg Neurol Int       Date:  2021-02-17

4.  Solitary bone plasmacytoma as posterior fossa cranial neoplasia, presentation of two clinical cases.

Authors:  Luis David Molina Andaluz; Josué Alejandro Cervantes Gonzalez; Zita Elizabeth Salazar Ramírez; Nelly Ramírez; Luis Guillermo Castellanos; Eric Misael Estrada Estrada
Journal:  Surg Neurol Int       Date:  2022-01-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.